locally advanced or metastatic breast cancer Breast Cancer
Conditions
Interventions
Abemaciclib (VERZENIO™)
Sponsors
Eli Lilly
Eligibility
Sex/Gender
Female
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria Patients eligible for inclusion in this study have to fulfill all of the following criteria: 1. Adult breast cancer female patients =18 years old at the start of receiving Abemaciclib, whether as a single-agent treatment or combination treatment 2. Premenopausal or postmenopausal patients with histologically proven HR-positive, HER2-negative with locally advanced or metastatic breast cancer (De-novo or recurrence/progression of early breast cancer) 3. Patients who are being treated or have been treated with Abemaciclib (VERZENIO™), whether as a single-agent treatment or combination treatment, for at least three months before data collection 4. Patients treated with Abemaciclib (VERZENIO™), whether as a single-agent treatment or combination treatment, according to the SmPC.
Exclusion criteria
Exclusion criteria: Exclusion criteria 1. Patients previously included in Abemaciclib clinical trial 2. Patients with evidence of other prior second primary concurrent malignancy apart from locally advanced or metastatic breast cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Name: Treatment patterns;Timepoints: 3;Measure: N/A | — |
Secondary
| Measure | Time frame |
|---|---|
| Name: Progression free survival;Timepoints: 3;Measure: N/A | — |
Countries
Kuwait, Lebanon
Contacts
Public ContactSarah Kharsa
CRO
Outcome results
None listed